Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2022-01-07 00:00:00 ET · period of report 2022-01-07 · accession 0001209191-22-002617 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-07 | 2022-01-07 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $5.19 | +11.8K | 4.06M | +0.3% | +$61.3K |
| D | 2022-01-07 | 2022-01-07 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $0.00 | -11.8K | 761.4K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-07 | M | A | 11,806 | $5.19 | 4,057,634 | D | — | — | (F1) Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole. |
| 2 | Derivative | Stock Option (right to buy Common Stock) | 2022-01-07 | M | D | 11,806 | $0.00 | 761,421 | D | $5.19 · 2012-03-01 to 2022-02-16 | 11,806 Common Stock | (F3) Represents total stock options beneficially owned at various strike prices. (F2) Represents first vesting date. Option vested over four years from date of grant. |